Search PubMed⌕ Search

Biomedical subjects

Anders Heijl

Publications and source records attributed to Anders Heijl.

30 records · Page 2Linked to original sources
PubMed2003

Measuring visual field progression in the Early Manifest Glaucoma Trial.

AIMS: The Early Manifest Glaucoma Trial (EMGT) (316 eligible eyes) has used a new set of criteria to define visual field progression in glaucoma. This paper provides estimates of the amount of visual field worsening required to reach the EMGT definition of definite perimetric progression. METHODS: In the 148 eyes that reached definite progression, we first determined changes between baseline and the time of definite EMGT progression, both for mean deviation (MD) and for number of highly (p < 0.5%) significantly depressed test points in pattern deviation probability maps. Second, we studied whether such changes depended on baseline MD, intraocular pressure (IOP), age and time to progression, all of which are factors that affect the rate of field progression. RESULTS: In eyes reaching progression, the mean change in MD from baseline was -1.93 dB (SE +/- 0.20) and the mean change in number of significant points was +4.85 (SE +/- 0.35). These changes did not show linear dependency on baseline MD, IOP or time to progression. CONCLUSIONS: The average amount of field deterioration needed to reach EMGT visual field progression has been measured and expressed in more conventional units (i.e. a loss of about - 2dB in MD and an increase in about five highly significant points). These estimates will facilitate the clinical interpretation of the results of EMGT.

Aged↗
PubMed2003

Electrophysiology and ocular blood flow in a family with dominant optic nerve atrophy and a mutation in the OPA1 gene.

OBJECTIVE: To characterize the clinical phenotype, with emphasis on electrophysiology and blood flow measurements, of a family with dominant optic nerve atrophy and an identified mutation in the OPA1 gene. METHODS: Seven family members were examined. Ophthalmological evaluation included testing of visual acuity, ophthalmolscopy, kinetic perimetry, color vision testing, full-field electroretinography (ERG), multifocal electroretinography (MERG), and multifocal visual evoked potential (MVEP). Retrobulbar arterial blood flow and retinal capillary perfusion was measured in three patients using scanning laser Doppler flowmetry (SLDF) and color Doppler imaging techniques. PCR-SSCP and DNA sequencing determined the presence of a mutation in exon 18 of the OPA1 gene. RESULTS: The clinical characteristics varied considerably in the family. The ERG and the MERG demonstrated normal retinal function, while the MVEP was abnormal in all examined patients. Retinal and optic nerve head capillary perfusion was significantly decreased in the three patients examined with SLDF. Retrobulbar blood flow velocities were significantly decreased in the central retinal and ophthalmic arteries. In all seven examined subjects, a microdeletion (1756-1767del(12 bp)) in the OPA1 gene was identified. CONCLUSION: Patients with a mutation in the OPA1 gene have a very variable phenotype. MVEP and blood flow measurements are two new objective methods for an easier detection of this specific genetic optic nerve atrophy.

Adolescent↗
PubMed2003

Nordic research in ophthalmology.

PURPOSE: To provide an overview of some of the current activities in eye research in the Nordic countries. METHODS: The presentations at the biannual Nordic Congress of Ophthalmology, held in Tampere, Finland in 2002, were reviewed and the contributions found most noteworthy are included in this article along with a limited discussion of each research field. However, space requirements prevented the inclusion of many interesting scientific contributions. RESULTS: Important contributions in various subfields of eye research and ophthalmology are reviewed. These include cornea, cataract, paediatric ophthalmology, glaucoma, diabetic eye disease, age-related macular degeneration, physiology and pharmacology and oncology. CONCLUSIONS: Eye research is very active in the Nordic countries and significant contributions are being made to ophthalmology in several fields on a world scale. We hope to continue to review Nordic contributions to eye research after each Nordic Congress of Ophthalmology and plan to make the reviews more systematic and comprehensive in the future.

Biomedical Research↗
PubMed2003

Normal intersubject threshold variability and normal limits of the SITA SWAP and full threshold SWAP perimetric programs.

PURPOSE: To compare intersubject variability and normal limits of threshold values between the new Swedish interactive test algorithm short wavelength automated perimetry (SITA SWAP) and the older Full Threshold SWAP programs (Carl Zeiss Meditec, Dublin, CA). METHODS: Normal reduction of differential light sensitivity with age, age-corrected thresholds, intersubject variability, and normal limits of sensitivity were calculated from SITA SWAP and Full Threshold SWAP fields obtained in 53 normal subjects between 20 and 72 years of age. RESULTS: Age influence on threshold sensitivity was the same with the two SWAP programs. On average, sensitivity decreased by 0.13 dB per year of age. Age-corrected normal threshold sensitivity was significantly higher (P<0.0001) for SITA SWAP than for Full Threshold SWAP. The means for a subject 45.4 years of age were 28.8 dB with SITA SWAP and 24.4 dB with Full Threshold SWAP. Intersubject variance was 22% smaller with SITA SWAP than with Full Threshold SWAP. Normal limits at the P<5% significance level were, on average, 14% narrower with SITA SWAP than with Full Threshold SWAP using Total Deviations from age-corrected normal thresholds and 11% narrower when applying Pattern Deviation, which is intended to adjust for general depression or elevation of the field. CONCLUSIONS: SITA SWAP test results from normal eyes showed higher sensitivities than results from the older Full Threshold SWAP. This represents an increase of the dynamic range, which implies that more patients can be tested with SWAP. The smaller intersubject variability with SITA SWAP means narrower normal limits and may be associated with more sensitive probability maps.

Adult↗
PubMed2002

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

OBJECTIVE: To provide the results of the Early Manifest Glaucoma Trial, which compared the effect of immediately lowering the intraocular pressure (IOP), vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma. DESIGN: Randomized clinical trial. PARTICIPANTS: Two hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening. Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible. INTERVENTIONS: Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126). Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months. Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter. MAIN OUTCOME MEASURES: Glaucoma progression was defined by specific visual field and optic disc outcomes. Criteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests. Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings. RESULTS: After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death. On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up. Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients. Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status. Although patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P =.002). CONCLUSIONS: The Early Manifest Glaucoma Trial is the first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP. Its intent-to-treat analysis showed considerable beneficial effects of treatment that significantly delayed progression. Whereas progression varied across patient categories, treatment effects were present in both older and younger patients, high- and normal-tension glaucoma, and eyes with less and greater visual field loss.

Adrenergic beta-Antagonists↗
PubMed2002

Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study.

PURPOSE: The aim of this study was to investigate the haemodynamic effects of topical dorzolamide treatment in eyes with newly detected and previously untreated glaucoma. METHODS: Forty-seven patients with open angle glaucoma were consecutively randomized to dorzolamide versus placebo TID during a 6-week double-masked treatment trial. Ocular blood flow was investigated at baseline and on therapy using colour Doppler imaging of the retrobulbar vessels and scanning laser ophthalmoscope fluorescein angiograms of the retinal circulation. RESULTS: None of the flow parameters, retrobulbar or retinal, changed significantly on therapy when the results were analysed with the Bonferroni method. Analysis with non-simultaneous tests also failed to reveal any significant changes either in retrobulbar flow velocities in the central retinal artery, ophthalmic artery or in the short posterior ciliary arteries, or in the retinal parameters (arm-retina time, arteriovenous passage time, mean dye velocity or macular capillary velocity), while capillary velocities at the optic disc decreased significantly in the dorzolamide group (P = 0.03). Intraocular pressure reduction was significantly more pronounced in the dorzolamide group (P = 0.002), with - 4.8 +/- 2.9 mmHg (P < 0.0001) versus -1.8 +/- 3.0 mmHg in the placebo group (P = 0.006). CONCLUSIONS: The present study indicated no measurable vascular effects from topical dorzolamide treatment in previously untreated glaucoma eyes.

Administration, Topical↗
PubMed2002

A comparison of glaucoma patients identified through mass screening and in routine clinical practice.

PURPOSE: To study differences between glaucoma patients identified through a population screening and glaucoma patients diagnosed in routine clinical practice (self-selected patients). METHODS: A total of 402 individuals with newly detected open-angle glaucoma were identified through a large population screening programme that ran from October 1992 to January 1997. The screening programme was attended by a total of 32918 citizens of Malmö, Sweden, aged between 57 and 79 years. Citizens who had visited the Eye Department of Malmö University Hospital in the year before the screening of their birth cohort were not invited to participate (n = 4117). Among the latter, we identified 354 patients with open-angle glaucoma through a retrospective examination of patient records. RESULTS: At detection, 52.9% of the glaucoma patients identified through screening had normal tension glaucoma (NTG), defined as intraocular pressure (IOP) < 21 mmHg in both eyes, compared to 13.5% of the self-selected patients (p < 0.0001). Mean IOP at the time of diagnosis was 22.9 mmHg in the screened group and 32.5 mmHg in the self-selected group. Pseudoexfoliation was present in 16.4% of the screened group and 44.0% of the self-selected group (p < 0.01). Bilateral disease was present in 40.1% of the screened group and 34.6% of the self-selected group (p = 0.1160). Median MD (mean deviation from the age-corrected normal visual field) in the worse eye was -8.0 dB in the screened group and -16.2 dB in the self-selected group (p < 0.0001). Visual acuity was lower in the self-selected group, which was also on average slightly more myopic. Of the patients detected through screening, 62% had seen an ophthalmologist previously, 17% within the preceding 2-year period. CONCLUSIONS: Normal tension glaucoma was four times as common in patients identified through population screening as in self-selected patients, suggesting that patients with NTG are easily overlooked in clinical practice. Even though the patients detected through population screening had lower mean IOP, lower prevalence of pseudoexfoliation, better visual fields and a lower incidence of bilateral disease than self-selected patients, many still had considerable damage. Special efforts, such as glaucoma screening, are needed if manifest glaucoma, and especially NTG, is to be detected at an earlier stage than it currently is.

Aged↗
PubMed2002

Optic disc hemorrhages and generalized vascular disease.

PURPOSE: To study the relationship between optic disc hemorrhages and four different groups of medications used in general vascular disease and diabetes. METHODS: The authors screened citizens of the city of Malmö, Sweden who were between 57 and 79 years old (32,918 subjects), in order to find individuals with undetected glaucoma. One set of optic disc photographs was taken of each participant and examined for optic disc hemorrhages. Logistic regression was used, with platelet aggregation inhibitors, antihypertensive agents, cholesterol-lowering medication, and antidiabetic agents as independent variables that were tested in isolation as well as in various combinations and adjusted for age and gender. RESULTS: Optic disc hemorrhages were significantly more common in individuals taking platelet aggregation inhibitors (OR 3.16, P < 0.0001). There was no significant association between ODH and the other three groups of medications. CONCLUSIONS: The significant relationship between platelet aggregation inhibitors and optic disc hemorrhages is a new and interesting finding that could indicate an association between optic disc hemorrhages and generalized vascular disease. Alternatively, it could mean that platelet aggregation inhibitors prolong resorption of or predispose to optic disc hemorrhages.

Aged↗